Publicaciones en colaboración con investigadores/as de University Medical Center Utrecht (68)

2024

  1. EUSOMA quality indicators for non-metastatic breast cancer: An update

    European Journal of Cancer, Vol. 198

  2. Experimentally-guided in silico design of engineered heart tissues to improve cardiac electrical function after myocardial infarction

    Computers in Biology and Medicine, Vol. 171

  3. International Myeloma Working Group immunotherapy committee consensus guidelines and recommendations for optimal use of T-cell-engaging bispecific antibodies in multiple myeloma

    The Lancet Oncology, Vol. 25, Núm. 5, pp. e205-e216

  4. Lack of association between classical HLA genes and asymptomatic SARS-CoV-2 infection

    Human Genetics and Genomics Advances, Vol. 5, Núm. 3

  5. Nivolumab with or without ipilimumab in patients with recurrent or metastatic cervical cancer (CheckMate 358): a phase 1–2, open-label, multicohort trial

    The Lancet Oncology, Vol. 25, Núm. 5, pp. 588-602

2023

  1. Clinical, dosimetric, and reporting considerations for Y-90 glass microspheres in hepatocellular carcinoma: updated 2022 recommendations from an international multidisciplinary working group

    European Journal of Nuclear Medicine and Molecular Imaging, Vol. 50, Núm. 2, pp. 328-343

  2. Defining textbook outcome for selective internal radiation therapy of hepatocellular carcinoma: an international expert study

    European Journal of Nuclear Medicine and Molecular Imaging, Vol. 50, Núm. 3, pp. 921-928

  3. European Groundshot—addressing Europe's cancer research challenges: a Lancet Oncology Commission

    The Lancet Oncology, Vol. 24, Núm. 1, pp. e11-e56

  4. Exploring the EVolution in PrognOstic CapabiLity of MUltisequence Cardiac MagneTIc ResOnance in PatieNts Affected by Takotsubo Cardiomyopathy Based on Machine Learning Analysis: Design and Rationale of the EVOLUTION Study

    Journal of Thoracic Imaging, Vol. 38, Núm. 6, pp. 391-398

  5. Genetically inferred birthweight, height, and puberty timing and risk of osteosarcoma

    Cancer Epidemiology

  6. Plain language summary of the MonumenTAL-1 study of talquetamab in people with relapsed or refractory multiple myeloma

    Future Oncology, Vol. 19, Núm. 27, pp. 1823-1840

  7. Report of Consensus Panel 6 from the 11 th International Workshop on Waldenström's Macroglobulinemia on Management of Waldenström's Macroglobulinemia Related Amyloidosis

    Seminars in Hematology

  8. Report of consensus Panel 4 from the 11th International Workshop on Waldenstrom's macroglobulinemia on diagnostic and response criteria

    Seminars in Hematology

2022

  1. Estimating Bleeding Risk in Patients with Cancer-Associated Thrombosis: Evaluation of Existing Risk Scores and Development of a New Risk Score

    Thrombosis and Haemostasis, Vol. 122, Núm. 5, pp. 818-829

  2. European experts consensus: BRCA/homologous recombination deficiency testing in first-line ovarian cancer

    Annals of Oncology, Vol. 33, Núm. 3, pp. 276-287

  3. Isolation methods of large and small extracellular vesicles derived from cardiovascular progenitors: A comparative study

    European Journal of Pharmaceutics and Biopharmaceutics, Vol. 170, pp. 187-196

  4. Outcome of allogeneic haematopoietic cell transplantation in eosinophilic disorders: A retrospective study by the chronic malignancies working party of the EBMT

    British Journal of Haematology

  5. Prospective validation of a new imaging scorecard to assess leptomeningeal metastasis: A joint EORTC BTG and RANO effort

    Neuro-oncology, Vol. 24, Núm. 10, pp. 1726-1735

2021

  1. Belantamab mafodotin in combination with novel agents in relapsed/refractory multiple myeloma: DREAMM-5 study design

    Future Oncology, Vol. 17, Núm. 16, pp. 1987-2003

  2. DNA methylation as the link between migration and the major noncommunicable diseases: The RODAM study

    Epigenomics, Vol. 13, Núm. 9, pp. 653-666